Qualitest Pharmaceuticals Receives FDA Approval for Myzilra™ Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP), 0.05 mg/0.03 mg, 0.075 mg/0.04 mg, 0.125 mg/0.03 mg (28 - Day TriPhasic Regimen)
HUNTSVILLE, Ala., Nov. 28, 2011 /PRNewswire/ -- Qualitest Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Myzilra Tablets (Levonorgestrel and Ethinyl Estradiol Tablets, USP), 0.05 mg/0.03 mg, 0.075 mg/0.04 mg, 0.125 mg/0.03 mg (28 - Day TriPhasic Regimen).
The total sales for Myzilra Tablets in the U.S. for the 12 months ended September 30, 2011 were approximately $34.4 million, according to IMS Health.
Founded in 1983, Qualitest provides affordable, high-quality generic pharmaceuticals. Featuring a current portfolio exceeding 600 products, the company has grown significantly since its inception and is now ranked in the top ten among all suppliers of generics, based on total prescriptions filled. Qualitest is a wholly owned subsidiary of Endo Pharmaceuticals (Nasdaq: ENDP), a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics (www.endo.com).
SOURCE Endo Pharmaceuticals